Hisense Home Appliances Group (00921) released its interim results, with a net profit attributable to the parent company of 1.658 billion yuan, a year-on-year decrease of 20.16%.
Hisense Appliances (00921) released its interim performance announcement for 2026, reporting total operating revenue of RMB 46.766 billion, a year-on-year decrease of 5.22%; net profit attributable to the parent company's owners was RMB 1.658 billion, a year-on-year decrease of 20.16%; earnings per share were RMB 1.21.
Hisense Home Appliances Group (00921) announced its mid-term performance for 2026, reporting total operating revenue of RMB 46.766 billion, a year-on-year decrease of 5.22%; net profit attributable to shareholders of the parent company was RMB 1.658 billion, a year-on-year decrease of 20.16%; earnings per share were RMB 1.21.
The announcement stated that the company is actively responding to the national green and low-carbon transformation strategy, continuously focusing on four major areas: upgrading central air conditioning energy efficiency, refrigerant management and green compliance, updating existing equipment, and promoting heat pumps, in order to support the HVAC industry in achieving sustainable high-quality development. According to statistics from the Industrial Online, during the reporting period, the domestic multi-split air conditioner market share reached 26.6%, continuing to lead the industry forward.
Related Articles

HJ SCIENCE-B (06132) recommends adopting the H-share incentive plan for 2026.

SKB BIO (06990) released its interim results, with shareholders' net profit reaching 388 million yuan, marking a turnaround from loss to profit compared to the same period last year.

BlackRock increased its holdings in INNOVENT BIO (01801) by 139,500 shares at a price of HKD 95.375 per share.
HJ SCIENCE-B (06132) recommends adopting the H-share incentive plan for 2026.

SKB BIO (06990) released its interim results, with shareholders' net profit reaching 388 million yuan, marking a turnaround from loss to profit compared to the same period last year.

BlackRock increased its holdings in INNOVENT BIO (01801) by 139,500 shares at a price of HKD 95.375 per share.

RECOMMEND





